4//SEC Filing
Quinlan Paul T 4
Accession 0001062993-23-022636
CIK 0001042074other
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 4:35 PM ET
Size
8.9 KB
Accession
0001062993-23-022636
Insider Transaction Report
Form 4
Quinlan Paul T
General Counsel
Transactions
- Sale
Common Stock
2023-12-15$21.98/sh−5,000$109,903→ 0 total - Exercise/Conversion
Common Stock
2023-12-15$2.94/sh+5,000$14,700→ 5,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-12-15−5,000→ 112,000 totalExercise: $2.94Exp: 2032-01-24→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.66 to $22.33, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022.
Issuer
CymaBay Therapeutics, Inc.
CIK 0001042074
Entity typeother
Related Parties
1- filerCIK 0001333277
Filing Metadata
- Form type
- 4
- Filed
- Dec 14, 7:00 PM ET
- Accepted
- Dec 15, 4:35 PM ET
- Size
- 8.9 KB